Overview
Description
Terumo Corp. engages in the manufacture and sale of medical products and equipment. It operates through the following segments: Cardiac and Vascular Company, General Hospital Company, and Blood Management Company. The Cardiac and Vascular Company segment offers services and treatments including cardiac and vascular surgery and interventional therapies performed inside blood vessels. The General Hospital Company segment provides infusion and closed anticancer drug infusion systems, measuring devices system with communication functions, diabetes management, adhesion barrier, and peritoneal dialysis. The Blood Management Company segment offers a combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction. The company was founded by Shibasaburo Kitasato on September 17, 1921 and is headquartered in Tokyo, Japan.
Healthcare Healthcare Equipment General Medical Devices Japan
Financials
Key metrics
| Market capitalisation, EUR | 18,412 m |
| EPS, EUR | 0.54 |
| P/B ratio | 2.3 |
| P/E ratio | 25.7 |
| Dividend yield | 1.23% |
Income statement (2024)
| Revenue, EUR | 6,339 m |
| Net income, EUR | 716 m |
| Profit margin | 11.29% |
What ETF is Terumo Corp. in?
There are 46 ETFs which contain Terumo Corp.. All of these ETFs are listed in the table below. The ETF with the largest weighting of Terumo Corp. is the Xtrackers Nikkei 225 UCITS ETF 1D.
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
